O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and Low MGMT-Encoded Protein Expression as Prognostic Markers in Glioblastoma Patients Treated with Biodegradable Carmustine Wafer Implants after Initial Surgery Followed by Radiotherapy with Concomitant and Adjuvant Temozolomide - Normandie Université Access content directly
Conference Papers Year : 2012

O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and Low MGMT-Encoded Protein Expression as Prognostic Markers in Glioblastoma Patients Treated with Biodegradable Carmustine Wafer Implants after Initial Surgery Followed by Radiotherapy with Concomitant and Adjuvant Temozolomide

Js Guillamo
  • Function : Author
G Levallet
A Dugué
  • Function : Author
A Vital
  • Function : Author
Md Diebold
  • Function : Author
P Menei
  • Function : Author
P Colin
  • Function : Author
P Peruzzy
  • Function : Author
E Emery
  • Function : Author
F Chapon
  • Function : Author
No file

Dates and versions

hal-02265457 , version 1 (09-08-2019)

Identifiers

  • HAL Id : hal-02265457 , version 1

Cite

Js Guillamo, G Levallet, A Dugué, A Vital, Md Diebold, et al.. O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and Low MGMT-Encoded Protein Expression as Prognostic Markers in Glioblastoma Patients Treated with Biodegradable Carmustine Wafer Implants after Initial Surgery Followed by Radiotherapy with Concomitant and Adjuvant Temozolomide. 64th Annual Meeting of the American-Academy-of-Neurology (AAN), Apr 2012, New Orleans, United States. pp.P06.004. ⟨hal-02265457⟩
29 View
0 Download

Share

Gmail Facebook X LinkedIn More